Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Research & Development: 2009-2025

Historic Research & Development for China Pharma Holdings (CPHI) over the last 13 years, with Sep 2025 value amounting to $40,321.

  • China Pharma Holdings' Research & Development fell 53.98% to $40,321 in Q3 2025 from the same period last year, while for Sep 2025 it was $91,407, marking a year-over-year decrease of 78.79%. This contributed to the annual value of $283,942 for FY2024, which is 18.27% up from last year.
  • Per China Pharma Holdings' latest filing, its Research & Development stood at $40,321 for Q3 2025, which was up 92.44% from $20,952 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Research & Development ranged from a high of $190,086 in Q1 2021 and a low of $547 during Q4 2024.
  • In the last 3 years, China Pharma Holdings' Research & Development had a median value of $31,451 in 2024 and averaged $55,898.
  • Over the last 5 years, China Pharma Holdings' Research & Development had its largest YoY gain of 592.02% in 2024, and its largest YoY loss of 99.63% in 2024.
  • China Pharma Holdings' Research & Development (Quarterly) stood at $54,048 in 2021, then tumbled by 48.20% to $27,999 in 2022, then skyrocketed by 426.99% to $147,552 in 2023, then slumped by 99.63% to $547 in 2024, then plummeted by 53.98% to $40,321 in 2025.
  • Its Research & Development was $40,321 in Q3 2025, compared to $20,952 in Q2 2025 and $29,587 in Q1 2025.